Aeterna Zentaris, Inc. Stock Price, News & Analysis

Aeterna Zentaris Inc. (NASDAQ: AEZS) announced an underwriting agreement with H.C. Wainwright & Co. for the sale of 6,896,552 common shares at $1.45 each, expected to close on February 19, 2021. Gross proceeds are projected to be around $10 million, aimed at corporate purposes including further development of its product, macimorelin. The underwriter has a 30-day option for an additional 1,034,482 shares. The offering follows a previous shelf registration filed with the SEC.

Aeterna Zentaris licenses exclusive worldwide rights to develop and commercialize AIM Biologicals for treating neuromyelitis optica spectrum disorder (NMOSD) from Julius-Maximilians-University Wuerzburg. This step aims to expand Aeterna's pipeline in a high-value orphan indication with significant unmet medical need. The license agreement includes a €100,000 upfront payment and further milestone and royalty payments. With only three approved NMOSD medications, the collaboration could address a pressing medical need, targeting approximately 10,000 to 15,000 patients in the U.S. and Europe.

Aeterna Zentaris (NASDAQ: AEZS) announced on January 26, 2021, that it has received a 180-day extension from Nasdaq to comply with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company has until July 26, 2021, to ensure its common shares close at or above $1.00 for ten consecutive days. Should it fail to meet this requirement, it may face delisting but can appeal the decision. The notification does not affect its listing on the Toronto Stock Exchange.

Aeterna Zentaris Inc. (NASDAQ: AEZS) announces that CEO Dr. Klaus Paulini will present at NobleCon17 on January 20, 2021, at 12:00 PM ET. The virtual conference is free to attend, and a high-definition video webcast will be available. Aeterna is focused on developing therapeutics, with its lead product, macimorelin, being the first FDA-approved oral test for adult growth hormone deficiency. The company plans to expand the commercialization of macimorelin in Europe and aims to leverage its success for childhood-onset growth hormone deficiency.

Aeterna Zentaris (NASDAQ: AEZS) announced that CEO Dr. Klaus Paulini will present at the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2021. The presentation will be available on-demand from January 11, 2021, at 6:00 AM ET for registered attendees. Aeterna Zentaris specializes in biopharmaceuticals, focusing on therapeutics and diagnostic tests, notably their lead product, macimorelin, which is FDA and European Commission approved for diagnosing adult growth hormone deficiency. The company aims to expand macimorelin's market in various regions.

Aeterna Zentaris (NASDAQ: AEZS) has entered a licensing agreement with Consilient Health for the commercialization of macimorelin in Europe and the UK. The agreement includes an upfront payment of €1 million and royalties ranging from 10% to 20% on net sales. Consilient will handle regulatory approvals and bear associated costs, including a pivotal Phase 3 study for childhood-onset growth hormone deficiency. Aeterna retains control over its patents in these regions and continues to explore additional partnerships for macimorelin's global commercialization.

Aeterna Zentaris has amended its License Agreement with Novo Nordisk, which includes an upfront payment of €5 million. This replaces a later regulatory milestone payment of U.S.$5 million. Novo Nordisk will also cover 100% of the costs for the upcoming AEZS-130-P02 clinical trial, up to €9 million. Following this amendment, Aeterna retains rights to macimorelin outside the U.S. and Canada, while Novo Nordisk will share co-ownership of patents. The royalty rate for U.S. sales will decrease from 15% to 8.5% until sales reach U.S.$40 million, returning to 15% thereafter.

Aeterna Zentaris Inc. (NASDAQ: AEZS) reported its Q3 2020 results, highlighting a net loss of $1.1 million, or $0.02 per share, compared to a loss of $0.3 million in Q3 2019. Total revenue decreased to $0.1 million from $0.3 million in the prior year, with operating expenses reduced to $1.9 million. The company raised $19 million in financing, regained Nasdaq compliance, and plans to initiate a pivotal Phase 3 study (AEZS-130-P02) for macimorelin in Q1 2021. Aeterna is also pursuing partnerships for macimorelin in Europe and exploring additional pipeline opportunities.

Aeterna Zentaris Inc. (AEZS) announced a corporate update highlighting recent funding achievements, securing $23.5 million this year, which enhances its cash runway and growth potential. The pivotal Phase 3 study AEZS-130-P02 is set to begin in Q1 2021, targeting childhood-onset growth hormone deficiency (CGHD). The company is also exploring new therapeutic uses for its lead product, macimorelin, and continues efforts to find commercialization partners in Europe. These initiatives position the company for future growth and diversification.